BCAX vs BCYC

Bicara Therapeutics Inc. vs Bicycle Therapeutics plc — Valuation Comparison 2026

BCAX

Biotechnology
Bicara Therapeutics Inc.
Quality
4.3
out of 10
Value Trap
12
SAFE
Price
$21.75
Last close
Models
7/13
Active
VS

BCYC

Biotechnology
Bicycle Therapeutics plc
Quality
6.1
out of 10
Value Trap
24
SAFE
Price
$4.67
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType BCAX Fair ValueBCAX Upside BCYC Fair ValueBCYC Upside
Bayesian DCF Intrinsic $8.47 -61.1% $5.55 +18.7%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $3.40 -84.4% $1.45 -67.3%
Dynamic NAV Asset-Based $6.66 -69.4% $9.86 +111.2%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for BCAX vs BCYC — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

BCAX vs BCYC — Which Stock Is More Undervalued?

BCYC scores higher with a 6.1/10 quality rating vs BCAX's 4.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Bicara Therapeutics Inc. (BCAX) and Bicycle Therapeutics plc (BCYC) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

BCAX currently trades at $21.75 with a QOC of 4.3/10, while BCYC trades at $4.67 with a QOC of 6.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).